Scientific Reports (Apr 2023)

Rewiring of the 3D genome during acquisition of carboplatin resistance in a triple-negative breast cancer patient-derived xenograft

  • Mikhail G. Dozmorov,
  • Maggie A. Marshall,
  • Narmeen S. Rashid,
  • Jacqueline M. Grible,
  • Aaron Valentine,
  • Amy L. Olex,
  • Kavita Murthy,
  • Abhijit Chakraborty,
  • Joaquin Reyna,
  • Daniela Salgado Figueroa,
  • Laura Hinojosa-Gonzalez,
  • Erika Da-Inn Lee,
  • Brittany A. Baur,
  • Sushmita Roy,
  • Ferhat Ay,
  • J. Chuck Harrell

DOI
https://doi.org/10.1038/s41598-023-32568-7
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 17

Abstract

Read online

Abstract Changes in the three-dimensional (3D) structure of the genome are an emerging hallmark of cancer. Cancer-associated copy number variants and single nucleotide polymorphisms promote rewiring of chromatin loops, disruption of topologically associating domains (TADs), active/inactive chromatin state switching, leading to oncogene expression and silencing of tumor suppressors. However, little is known about 3D changes during cancer progression to a chemotherapy-resistant state. We integrated chromatin conformation capture (Hi-C), RNA-seq, and whole-genome sequencing obtained from triple-negative breast cancer patient-derived xenograft primary tumors (UCD52) and carboplatin-resistant samples and found increased short-range (< 2 Mb) interactions, chromatin looping, formation of TAD, chromatin state switching into a more active state, and amplification of ATP-binding cassette transporters. Transcriptome changes suggested the role of long-noncoding RNAs in carboplatin resistance. Rewiring of the 3D genome was associated with TP53, TP63, BATF, FOS-JUN family of transcription factors and led to activation of aggressiveness-, metastasis- and other cancer-related pathways. Integrative analysis highlighted increased ribosome biogenesis and oxidative phosphorylation, suggesting the role of mitochondrial energy metabolism. Our results suggest that 3D genome remodeling may be a key mechanism underlying carboplatin resistance.